Discovery of novel MDM2 inhibitor with antitumor activity in p53 wild-type cancer models March 14, 2022
Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent Nav1.8 channel blockers March 14, 2022